TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16941972
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of Antongding Injectio
Study: 9183333
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (low fixed dose warfarin plus aspirin)
Study: 23291425
Drug: NeuroFlo therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeuroFlo therapy
Study: 16830143
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg intravenously every 3 months for 12 months
Study: 8138867
Drug: Treatment instituted
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment instituted at bedtime
Study: 29127813
Drug: Culturally Sensitive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally Sensitive Collaborative Treatment (CSCT)
Study: 26802916
Drug: Medication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication therapy management (MTM) intervention targeting FRIDs
Study: 20349201
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment (specifics not provided)
Study: 19167586
Drug: Tizanidine 6-mg
Normalized name: tizanidine 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine 6-mg capsule administered intact
Study: 19167586
Drug: Tizanidine capsule
Normalized name: Tizanidine Capsules
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tizanidine capsule contents sprinkled in applesauce
Study: 16520204
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia (PCA)
Study: 19641359
Drug: Tamsulosin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.2 mg/day)
Study: 21617983
Drug: Tamsulosin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.2 mg/day) + Tolterodine (2 mg/day)
Study: 12534446
Drug: Iloprost administered
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost administered for 5 days in SSc patients
Study: 9842825
Drug: Epidural sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural sufentanil and morphine combined with bupivacaine
Study: 9842825
Drug: Intravenous sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sufentanil (IV)
Study: 8017740
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg enoxaparin every 12 hours
Study: 30149414
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (control)
Study: 27471836
Drug: Laparoscopic uterine
Normalized name: gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laparoscopic uterine artery occlusion in combination with laparoscopic myomectomy (LUAO+LM)
Study: 18786762
Drug: Treatment-Based Classification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-Based Classification (TBC)
Study: 15824161
Drug: 200 mg/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/wk oral oltipraz
Study: 12451428
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (250 ml) with diltiazem (120 mg)
Study: 12451428
Drug: Water with
Normalized name: sterile water with electrolytes injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water with diltiazem (120 mg)
Study: 10511903
Drug: Antibiotics for
Normalized name: ANTIBIOTICS FOR TOPICAL USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for initial treatment of bacterial complications of acute respiratory tract viral infections
Study: 7713831
Drug: Melatonin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin administration (100 mg at 0800)
Study: 26696199
Drug: Symptomatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic therapy (ST)
Study: 23332481
Drug: Behavioral health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral health music therapy intervention
Study: 21865716
Drug: Nasal submucosal
Normalized name: mepivacaine
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal submucosal administration of α‐GalCer‐pulsed DCs
Study: 17503545
Drug: Structured group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured group reminiscence therapy (8 sessions, 1 session per week)
Study: 6840159
Drug: Nifedipine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (all doses)
Study: 26386560
Drug: wPTX (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: wPTX (80 mg/m² on days 1, 8, and 15, every 4 weeks)
Study: 23982995
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 1 mg
Study: 3310158
Drug: Diltiazem 5
Normalized name: dilTIAZem 5 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 5 mg
Study: 9806261
Drug: 6% hydroxyethyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydroxyethyle starch solution (HES)
Study: 18200389
Drug: Dialectic‐didactic method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectic‐didactic method therapy (40 sessions) for research group (RG)
Study: 11157185
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg daily for 14 days
Study: 1836920
Drug: Plasma-derived hepatitis
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-derived hepatitis B vaccine
Study: 28333301
Drug: Total cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total cholesterol ≥200 mg/dl
Study: 28333301
Drug: Low HDL-C
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low HDL-C <50 mg/dl
Study: 28333301
Drug: Elevated triglycerides
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated triglycerides ≥150 mg/dl
Study: 25113095
Drug: Inhaled terbutaline
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline (30 × 0.5 mg)
Study: 22296762
Drug: Counting pills
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Counting pills method (Intervention group)
Study: 22296762
Drug: Counting pills
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Counting pills method (Control group)
Study: 15101854
Drug: Peritoneal dialysis
Normalized name: Peritoneal dialysis solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritoneal dialysis fluid infusion (2000 ml)
Study: 9635370
Drug: Granulocyte colony
Normalized name: Granulocyte colony stimulating factor
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Granulocyte colony stimulating factor (G‐CSF) therapy
Study: 9635370
Drug: Stem cell
Normalized name: Stem cells, apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stem cell factor (SCF) therapy
Study: 2805603
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein diet (NPD) 1 g/kg ideal body weight
Study: 2805603
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein diet (LPD) 0.5 g/kg ideal body weight
Study: 29369454
Drug: 10-day concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day concomitant therapy (rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, metronidazole 500 mg twice daily)
Study: 29369454
Drug: 14-day PAM-B
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day PAM-B therapy (rabeprazole 20 mg, amoxicillin 1 g, metronidazole 750 mg, tripotassium dicitrato bismuthate 600 mg twice daily)
Study: 27373556
Drug: Bushen capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bushen capsule
Study: 25467540
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioural self-help treatment consisting of 14 modules over 8 weeks with weekly email feedback from a clinical psychologist.
Study: 25467540
Drug: Wait-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-list control group receiving treatment after 8 weeks.
Study: 18312060
Drug: Levetiracetam 500
Normalized name: levetiracetam 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam 500 mg/day to 3000 mg/day
Study: 15881484
Drug: Daytime administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daytime administration of miconazole nitrate 1200 mg vaginal ovule
Study: 12657915
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 20 mg nefopam hydrochloride solution
Study: 26931055
Drug: Fluvoxamine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (200 mg daily) plus NAC (2000 mg daily)
Study: 26931055
Drug: Fluvoxamine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (200 mg daily) plus placebo
Study: 24686045
Drug: Perineural saline/2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perineural saline/2 mL with 50 mL normal saline
Study: 24686045
Drug: Perineural dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perineural dexamethasone 8 mg/2 mL
Study: 22271538
Drug: Waitlist, no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist, no treatment control
Study: 18381573
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 2 mg/d subcutaneously for 8 weeks
Study: 7860757
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion at 1.0 mU/kg-1 per min-1
Study: 7860757
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (both low and high)
Study: 19684522
Drug: Outpatient oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient oral ofloxacin 7.5 mg/kg 12 hourly and amoxycillin‐clavulanate 12.5 mg/kg 8 hourly
Study: 19684522
Drug: Outpatient intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient intravenous (IV) ceftriaxone 75 mg/kg and amikacin 15 mg/kg once daily
Study: 19684522
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and IV arms
Study: 15040503
Drug: Medroxyprogesterone 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medroxyprogesterone 30 mg twice daily
Study: 15040503
Drug: Acetazolamide 250
Normalized name: acetazolamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 250 mg plus medroxyprogesterone 30 mg twice daily
Study: 15040503
Drug: Acetazolamide 250
Normalized name: acetazolamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 250 mg plus placebo twice daily
Study: 31115552
Drug: Nutraceutical supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical supplements (NS)
Study: 16340560
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment followed by delayed laparoscopic cholecystectomy (DLC)
Study: 3636340
Drug: Timentin (ticarcillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timentin (ticarcillin 3 g plus potassium clavulanate 200 mg)
Study: 3636340
Drug: Piperacillin (125-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (125-200 mg/kg per day)
Study: 29229498
Drug: Once-daily, modified-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily, modified-release hydrocortisone
Study: 22276959
Drug: Drug Burden
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Burden Index (DBI) low category (n=260)
Study: 22276959
Drug: Drug Burden
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Burden Index (DBI) high category (n=153)
Study: 19011281
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 2.8 g/day
Study: 19011281
Drug: Docosahexaenoic acid
Normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docosahexaenoic acid (DHA) 2.9 g/day
Study: 10656230
Drug: Adding metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adding metformin
Study: 24941816
Drug: Ketamine 1
Normalized name: ketamine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 1 mg/(kg x h)
Study: 20621660
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg OpunDia
Study: 12391494
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous prednisone in combination with intramuscular polyvitaminic therapy (group A)
Study: 12391494
Drug: Polyvitaminic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyvitaminic therapy alone (group B)
Study: 2363111
Drug: Disodium monofluorophosphate
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium monofluorophosphate with calcium salts (100 mg disodium monofluorophosphate, 500 mg calcium)
Study: 9205772
Drug: Control preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control preparation (not specified)
Study: 28734759
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg every 2 weeks until disease progression, death, unacceptable toxic effects, or withdrawal from study.
Study: 25887365
Drug: Non-pharmacological multidisciplinary
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmacological multidisciplinary face-to-face treatment program (6 weeks, 7 group sessions)
Study: 25887365
Drug: Telephone-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based treatment program (6 weeks, 2 group sessions + 4 telephone contacts)
Study: 25887365
Drug: Non-pharmacological multidisciplinary
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmacological multidisciplinary face-to-face treatment program
Study: 11589530
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 to 200 mg/day
Study: 6757621
Drug: Polyunsaturated phosphatidyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyunsaturated phosphatidyl choline therapy (3 g/day)
Study: 6757621
Drug: Normal maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal maintenance immunosuppressive therapy
Study: 22893167
Drug: Cognitive-behavioral conjoint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral conjoint therapy for PTSD (15 sessions)
Study: 19922797
Drug: Post-PCI statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-PCI statin therapy
Study: 10639356
Drug: Teicoplanin (TEC)
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (TEC) 400 mg in 100 ml of saline as a 5‐min infusion into a foot vein of the leg to be operated on, administered immediately after the tourniquet was inflated to 400 mm Hg.
Study: 1906399
Drug: Aspirin (1300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1300 mg/day)
Study: 6614965
Drug: 20% 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% 5-fluorouracil (5-FU) ointment applied topically for four weeks
Study: 22191426
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 17β‐estradiol in non-smokers
Study: 22191426
Drug: Estrogen group
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen group (1 mg 17β‐estradiol)
Study: 21327805
Drug: Melatonin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 0.1 mg/kg
Study: 20668840
Drug: Melatonin 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 0.15 mg/kg
Study: 18001879
Drug: Cetirizine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 25 mg (CE) with alcohol 0.8 g/kg (AL)
Study: 18001879
Drug: Alcohol 0.8
Normalized name: isopropyl alcohol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol 0.8 g/kg (AL)
Study: 1773412
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of iohexol 240 (24 g iodine)
Study: 31350646
Drug: No Radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Radiotherapy (RT) administered to 141 patients (17.3%)
Study: 24935072
Drug: ticagrelor 45
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ticagrelor 45 mg bid
Study: 24935072
Drug: ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ticagrelor 90 mg bid
Study: 15302800
Drug: Rofecoxib (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (25 mg) daily for 6 months
Study: 2668979
Drug: Moclobemide 50
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 50 mg capsules
Study: 129494
Drug: Oral tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tetracycline (500 mg/day)
Study: 129494
Drug: Topical tetracycline
Normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracycline (0.5% solution applied twice daily)
Study: 17165243
Drug: Immediate-release nicotinic
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release nicotinic acid
Study: 7573093
Drug: Sustained-release nicotinic
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release nicotinic acid
Study: 8251351
Drug: Mantoux test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mantoux test (tuberculin injection)
Study: 20421151
Drug: Proton beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton beam therapy and capecitabine (825 mg/m² b.i.d. for 10 days)
Study: 20421151
Drug: Proton beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton beam therapy and capecitabine
Study: 18653493
Drug: Pregabalin 300
Normalized name: pregabalin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 300 mg + Dexamethasone 8 mg
Study: 8222739
Drug: Indomethacin suppository
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin suppository (100 mg)
Study: 3100675
Drug: Codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine phosphate 15 mg
Study: 24469645
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (daily hydration of 2500 mL, ciprofloxacin, diclofenac sodium, spasmolytic agent)
Study: 16101362
Drug: Surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical periodontal treatments (four different surgical procedures)
Study: 1453290
Drug: Group II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II: 1 gram of Cefazolin IV and 1 gram in saline irrigation solution
Study: 6377793
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of methyldopa/hydrochlorothiazide/amiloride (M/HCT/A)
Study: 29893596
Drug: Placebo (inert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inert pills)
Study: 18614728
Drug: Porridge with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porridge with energy density of 0.5 kcal/g
Study: 18614728
Drug: Porridge with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porridge with energy density of 1.0 kcal/g
Study: 8949813
Drug: Midazolam 0.1
Normalized name: midazolam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.1 mg
Study: 8949813
Drug: Propofol 3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3.3 mg
Study: 23761651
Drug: 30 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/d of hazelnuts
Study: 15996416
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied two times per week for 16 weeks
Study: 8843209
Drug: Pentoxifylline (1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (1800 mg/day, timed-release formulation)
Study: 1355585
Drug: Somatostatin analogues
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin analogues (e.g., octreotide)
Study: 31368267
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia (PCEA, Sufentainil + 0.1% Ropivacaine hydrochloride, 5 µg/mL at L3‐L4 interspace)
Study: 31368267
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection of Ropivacaine (0.2%, 1 mL/acupoint at LI4 and SP6)
Study: 22826982
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection therapy with diluted epinephrine (group I)
Study: 22826982
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of epinephrine and hemoclips (group II)
Study: 18506129
Drug: Propionyl-L-carnitine (PLC)
Normalized name: glycine propionyl-L-carnitine
DrugBank: Levocarnitine propionate (DB15980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl-L-carnitine (PLC) therapy at a dosage of 1,200 mg PLC in 250 cc of physiological solution for 5 days a week for 4 weeks